Table 1.
The clinicopathological features of breast cancer patients
| Characteristics | Number of patients, n (%) |
|---|---|
| Age range: 25‐64 | |
| Mean age: 43 | |
| Median age: 43 | |
| ER statusa | |
| Positive | 39 (79.6) |
| Negative | 8 (16.3) |
| Unknown | 2 (4.1) |
| PR statusa | |
| Positive | 31 (63.2) |
| Negative | 16 (32.7) |
| Unknown | 2 (4.1) |
| HER‐2 statusb | |
| Positive | 20 (40.8) |
| Negative | 24 (49.0) |
| Unknown | 5 (10.2) |
| Ki‐67 proteinc | |
| High (>14%) | 45 (91.8) |
| Low | 2 (4.1) |
| Unknown | 2 (4.1) |
| Tumor sized | |
| Tis | 3 (6.1) |
| T1 | 19 (38.8) |
| T2 | 20 (40.8) |
| T3 | 6 (12.2) |
| Unknown | 1 (2.0) |
| Lymph nodese | |
| N0 | 34 (69.4) |
| N1 | 8 (16.3) |
| N2 | 5 (10.2) |
| Unknown | 2 (4.1) |
| Metastasisf | |
| M0 | 45 (91.8) |
| M1 | 2 (4.1) |
| Unknown | 2 (4.1) |
| Histological tumor grade | |
| Tis (0) | 3 (6.1) |
| I | 16 (32.7) |
| II | 20 (40.8) |
| III | 6 (12.2) |
| IV | 3 (6.1) |
| Unknown | 1 (2.0) |
| Molecular subtypes | |
| HER‐2 over‐expression | 7 (14.3) |
| Luminal A | 4 (8.2) |
| Luminal B | 31 (63.3) |
| Triple negative | 2 (4.1) |
| Unknown | 5 (10.2) |
ER (estrogen receptor)/PR (progesterone receptor) negative: Immunoreactive score (IRS) ≤2; ER/PR positive: IRS >2 but ≤12.
HER‐2 (human epidermal growth factor 2) negative: IHC‐score ≤1; HER‐2 positive: IHC‐score >3.
Ki‐67 protein is a cellular marker for proliferation.
Tis: tumor in situ; T1: Tumor ≤2 cm; T2: Tumor >2 cm but ≤5 cm; T3: Tumor >5 cm.
N0: No regional lymph node metastasis; N1: Metastasis to movable ipsilateral lymph node(s); N2: Metastasis in ipsilateral axillary lymph node(s) fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastasis.
M0: No distant metastasis; M1: Metastasis to distant organs (beyond regional lymph nodes).